Background: “Hospital at Home” (HaH) models of care have existed for over 20 years in the U.S. Recent demand for healthcare value, advances in relevant technologies, and the ongoing global pandemic have driven renewed attention to HaH models, including from the Center for Medicare and Medicaid Services (CMS), and have spawned several pilots within the […]

Background: Hospital-at-Home (HaH) is a safe and effective alternative to high-cost, traditional hospitalization in patients with a range of medical conditions, such as non-severe community-acquired pneumonia (CAP). The COVID-19 pandemic created a unique situation with favorable policy changes, hospital resource constraints, and a clearly defined patient population that helped to increase HaH program deployment and […]

Background: Hospital at home (HaH) programs have provided critical inpatient-level care to acutely ill patients throughout the COVID-19 pandemic.1 Despite the documented benefits2-5, referral rates for HaH often mirror capacity demands. The pattern reflects implementation barriers including the tendency to default to usual care and time constraints.6 Continued success of HaH hinges on the question […]

Background: The ongoing global COVID-19 pandemic has stressed patients, hospital systems, and society and, while treatment modalities are continuously evolving. A phase 3 clinical trial of monoclonal antibody infusion in appropriate patients with Casirivimab and Imbdevimab demonstrated a 70% reduction in hospitalization or all-cause death compared to placebo (ref 1). An emergency use authorization by […]